Advertisement · 728 × 90
#
Hashtag
#polybio2026countdown
Advertisement · 728 × 90

Thank you to everyone who supported our work this year including donors, patients, and healthy controls in our trials.

#polybio2026countdown

2 0 0 0
Post image

No.11 on our 2026 countdown: PolyBio began a collaboration with 60 Degrees Pharma on a clinical trial of Tafenoquine for Chronic Babesiosis. The trial is a crucial step forward in finding effective therapies for the disease, which currently has no FDA-approved treatments.
#polybio2026countdown

3 0 0 0
Preview
Development of advanced diagnostics to identify the Babesia parasite - PolyBio Research Foundation Project Summary:To develop novel enrichment culture, serological, and visualization methods for the diagnosis of the parasite Babesia in people with a...

Read the project summary here:
polybio.org/projects/dev...

#polybio2026countdown

3 0 0 0
Preview
PolyBio Research Foundation Organizes Banbury Meeting on Accessible Diagnostics of Pathogen Tissue Persistence - PolyBio Research Foundation Lloyd Harbor, NY — December 7–10, 2025 — PolyBio Research Foundation convened and funded a Banbury Meeting at Cold Spring Harbor Laboratory,...

2/ Read the full news story here: polybio.org/polybio-rese...

#polybio2026countdown

3 2 0 0
Post image

No.8 on our list of influential PolyBio moments in 2025: the expansion of LIINC to study pre-2019 ME/CFS. The study will investigate key biological drivers of ME/CFS, including persistent gut enterovirus infections and T-cell over-activation in the CNS.
#polybio2026countdown

9 1 2 0
Post image

2025 was the year that PolyBio began launching several clinical trials—importantly, the RCT of repurposed HIV antivirals Truvada & Maraviroc for Long Covid at the CoRE clinic.
#polybio2026countdown

11 1 1 0
Post image

One of our favourite highlights of the year at PolyBio: Dr. Amy Proal’s TedX talk on the pathogen drivers of human aging.

“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”

#polybio2026countdown

8 1 2 0
Post image

A key contribution to the field this year by Dr. Amy Proal, PolyBio President & CEO, was her LA Times Op-Ed—a call-to-arms to both government agencies and private organizations to support Long Covid clinical trials.

www.latimes.com/opinion/stor...

#polybio #polybio2026countdown

6 2 0 0
Preview
PolyBio and WE&ME supported study identifies two distinct ME/CFS subtypes - PolyBio Research Foundation Medford MA - May 16, 2025 - A PolyBio-supported study published today in the Journal of Immunology sheds new light on the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) disease process.

Learn more about the study and its results here: polybio.org/polybio-and-...

#polybio2026countdown

3 0 0 0
Post image

Next up in PolyBio’s influential moments of 2025: we began supporting a clinical trial of low-dose Rapamycin for Long Covid at NYC’s Mount Sinai CoRE clinic. The ongoing study is assessing how patients’ immune markers (i.e. T-cell function) change over time. #polybio2026countdown

7 0 1 0
Post image

One of PolyBio’s most notable moments of 2025 was the publication of the ‘Long Covid Roadmaps paper,’ which brought together 30+ global experts. The paper was the first of its kind, discussing treatment strategies targeting the SARS-CoV-2 viral reservoir in Long Covid.
#polybio2026countdown

5 2 1 0
Post image

We’re counting down to the new year in the best way we know how: by looking back at 12 of PolyBio’s most influential moments of 2025. Follow along with us to recap key research in the complex chronic illness space this year. #polybio2026countdown

2 0 0 0